AZD-3965 is primarily investigated for its potential in cancer therapy, particularly in targeting cancer cells that rely heavily on glycolysis for energy production. It functions as a monocarboxylate transporter 1 (MCT1) inhibitor, which disrupts the lactate transport essential for the survival and proliferation of these cancer cells. This makes it a promising candidate for treating tumors with high glycolytic activity, such as certain types of lymphoma and solid tumors. Research is ongoing to evaluate its efficacy in combination with other therapies, aiming to enhance its anticancer effects and overcome resistance mechanisms. Additionally, its role in modulating the tumor microenvironment is being explored to improve immune responses against cancer.